Related references
Note: Only part of the references are listed.First results on survival from a large Phase 3 clinical trial of an autologous dendritic cell vaccine in newly diagnosed glioblastoma
Linda M. Liau et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2018)
Towards Improvements for Penetrating the Blood-Brain Barrier-Recent Progress from a Material and Pharmaceutical Perspective
Quanguo He et al.
CELLS (2018)
Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma A Randomized Clinical Trial
Roger Stupp et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2017)
Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial
Michael Weller et al.
LANCET ONCOLOGY (2017)
Enhancement of glioma-specific immunity in mice by NOBEL, an insulin-like growth factor 1 receptor antisense oligodeoxynucleotide
Melanie Morin-Brureau et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2015)
Transferrin receptors and glioblastoma multiforme: Current findings and potential for treatment
Brittany Voth et al.
JOURNAL OF CLINICAL NEUROSCIENCE (2015)
The role of regulatory T-cells in glioma immunology
Yinn Cher Ooi et al.
CLINICAL NEUROLOGY AND NEUROSURGERY (2014)
The Future of Glioblastoma Therapy: Synergism of Standard of Care and Immunotherapy
Mira A. Patel et al.
CANCERS (2014)
Resistance of Glioblastoma-Initiating Cells to Radiation Mediated by the Tumor Microenvironment Can Be Abolished by Inhibiting Transforming Growth Factor-β
Matthew E. Hardee et al.
CANCER RESEARCH (2012)
Novel CCL21-Vault Nanocapsule Intratumoral Delivery Inhibits Lung Cancer Growth
Upendra K. Kar et al.
PLOS ONE (2011)
CCR7-Dependent Immunity during Acute Toxoplasma gondii Infection
Shahani Noor et al.
INFECTION AND IMMUNITY (2010)
Vault Nanoparticles Containing an Adenovirus-Derived Membrane Lytic Protein Facilitate Toxin and Gene Transfer
Cheng-Yu Lai et al.
ACS NANO (2009)
CCL21 mediates CD4+ T-cell costimulation via a DOCK2/Rac-dependent pathway
Kathrin Gollmer et al.
BLOOD (2009)
A Vault Nanoparticle Vaccine Induces Protective Mucosal Immunity
Cheryl I. Champion et al.
PLOS ONE (2009)
Pre-clinical characterization of GMP grade CCL21-gene modified dendritic cells for application in a phase I trial in Non-Small Cell Lung Cancer
Felicita Baratelli et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2008)
Persistence of CD133+ cells in human and mouse glioma cell lines:: detailed characterization of GL261 glioma cells with cancer stem cell-like properties
Anhua Wu et al.
STEM CELLS AND DEVELOPMENT (2008)
Local expression of secondary lymphoid tissue chemokine delivered by adeno-associated virus within the tumor bed stimulates strong anti-liver tumor immunity
Chun-min Liang et al.
JOURNAL OF VIROLOGY (2007)
Characterization of the CCL21-mediated melanoma-specific immune responses and in situ melanoma eradication
Laura Novak et al.
MOLECULAR CANCER THERAPEUTICS (2007)
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma
R Stupp et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Nanoparticle surface charges alter blood-brain barrier integrity and permeability
PR Lockman et al.
JOURNAL OF DRUG TARGETING (2004)
A ligand for the chemokine receptor CCR7 can influence the homeostatic proliferation of CD4 T cells and progression of autoimmunity
C Ploix et al.
JOURNAL OF IMMUNOLOGY (2001)
Assembly of vault-like particles in insect cells expressing only the major vault protein
AG Stephen et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2001)
Secondary lymphoid tissue chemokine mediates T cell-dependent antitumor responses in vivo
S Sharma et al.
JOURNAL OF IMMUNOLOGY (2000)
The role of chemokines in the micro environmental control of T versus B cell arrest in Peyer's patch high endothelial venules
RA Warnock et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2000)
Share Paper
